View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 30, 2016

PathoQuest obtains CE mark for iDTECT blood test

French biotechnology company PathoQuest has received CE mark for its iDTECT blood test for clinical identification of pathogens from blood samples.

French biotechnology company PathoQuest has received CE mark for its iDTECT blood test for clinical identification of pathogens from blood samples.

The iDTECT blood test represents a next generation sequencing (NGS)-based metagenomics approach which has been developed to provide a clinically improved method of detection of bacteria and viruses in blood samples derived from patients suspected with infections or immunocompromised patients.

Hôpital Necker-Enfants Malades infectious and tropical diseases department chair and professor Olivier Lortholary said: “In some clinical situations, especially when a patient is immunocompromised, culture and PCR tests are often unable to provide sufficient information to select the most appropriate targeted anti-infective therapy.

"CE marking of the iDTECT Blood test is a major milestone for PathoQuest."

“With the availability of iDTECT Blood, clinicians will be able to expand their experience on the basis of the results already obtained in a proof-of-concept study completed at Necker-Enfants Malades and Européen Georges Pompidou hospitals (Paris, France) on a cohort of over 100 immuno-compromised patients.”

The iDTECT blood test uses PathoQuest’s proprietary methods to prepare blood samples and analyse it by leveraging the latest NGS-based technology to identify genomic sequences of pathogens in patient’s blood.

The genomic sequences, after being identified, are then compared to a comprehensive and curated database developed by PathoQuest which features genomics sequences from over 1,200 bacteria and viruses.

PathoQuest CEO Jean-Francois Brepson said: “CE marking of the iDTECT Blood test is a major milestone for PathoQuest.

“It validates the robustness of our sample-to-BioIT analysis solution, driven by PathoQuest’s proprietary iDTECT database and software.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU